Bibliografia AGE Reader

13. A new gender-specific model for skin autofluorescence risk stratification. Ahmad MS, Damanhouri ZA, Kimhofer T, Mosli HH, Holmes E. Sci Rep. 2015;5:10198. doi:10.1038/srep10198

14. Advanced glycation end-products, cardiac function and heart failure in the general population: The Rotterdam Study. Arshi B, Chen J, Ikram MA, Zillikens MC, Kavousi M. Diabetologia. Published online November 8, 2022. doi:10.1007/s00125-022-05821-3

15. Lens fluorescence and skin fluorescence in the Copenhagen Twin Cohort Eye Study: Covariates and heritability. Bjerager J, Dabbah S, Belmouhand M, Rothenbuehler SP, Sander B, Larsen M. PLOS ONE. 2021;16(9):e0256975. doi:10.1371/journal.pone.0256975

16. Advanced glycation end-products (AGEs) and associations with cardio-metabolic, lifestyle, and dietary factors in a general population: the NQplus study. Botros N, Sluik D, van Waateringe RP, de Vries JHM, Geelen A, Feskens EJM. Diabetes Metab Res Rev. 2017;33(5). doi:10.1002/dmrr.2892

17. The association between dietary and skin advanced glycation end products: the Rotterdam Study. Chen J, Waqas K, Tan RC, et al. Am J Clin Nutr. 2020;112(1):129-137. doi:10.1093/ajcn/nqaa117

18. Skin Autofluorescence Mirrors Surrogate Parameters of Vascular Aging: An Enable Study. Du T, Brandl B, Hauner H, Skurk T. Nutrients. 2023;15(7):1597. doi:10.3390/nu15071597

19. Skin advanced glycation end-products evaluation in infants according to the type of feeding and mother’s smoking habits. Federico G, Gori M, Randazzo E, Vierucci F. SAGE Open Med. 2016;4:2050312116682126. doi:10.1177/2050312116682126

20. Serum biomarkers, skin autofluorescence and other methods. Which parameter better illustrates the relationship between advanced glycation end products and arterial stiffness in the general population? Gelzinský J, Mayer O, Seidlerová J, et al. Hypertens Res. 2021;44(5):518-527. doi:10.1038/s41440-020-00601-1

21. Association of advanced glycation end products, evaluated by skin autofluorescence, with lifestyle habits in a general Japanese population. Isami F, West BJ, Nakajima S, Yamagishi SI. J Int Med Res. 2018;46(3):1043-1051. doi:10.1177/0300060517736914

22. Evaluation of skin autofluorescence as a surrogate of advanced glycation end products accumulation in children and adolescents with normal haemoglobin A1c values. Jankowska M, Bobeff K, Baranowska-Jazwiecka A, et al. Pediatr Endocrinol Diabetes Metab. 2020;26(1):1-9. doi:10.5114/pedm.2020.93251

23. Skin autofluorescence of Advanced Glycation End-products and mortality in older adults: The roles of chronic kidney disease and diabetes. Majchrzak C, Cougnard-Gregoire A, Le-Goff M, et al. Nutr Metab Cardiovasc Dis. Published online August 13, 2022:S0939-4753(22)00336-2. doi:10.1016/j.numecd.2022.08.009

24. Skin autofluorescence and glycemic variability. Noordzij MJ, Lefrandt JD, Graaff R, Smit AJ. Diabetes Technol Ther. 2010;12(7):581-585. doi:10.1089/dia.2010.0014

25. The role of Carcinine treatment on glico-lipidic imbalance of patients with altered blood glucose pattern. Palmieri B, Vadalà M.

26. Early vascular aging as an index of cardiovascular risk in healthy adults: confirmatory factor analysis from the EVasCu study. Saz-Lara A, Cavero-Redondo I, Pascual-Morena C, et al. Cardiovasc Diabetol. 2023;22(1):209. doi:10.1186/s12933-023-01947-9

27. Associations between birth parameters and skin autofluorescence advanced glycation end and ankle-brachial index in young adulthood: the Malmö Offspring Study. Sharma S, Sperling J, Jujic A, Bennet L, Christensson A, Nilsson PM. J Hypertens. Published online April 26, 2023. doi:10.1097/HJH.0000000000003449

28. Skin autofluorescence as tool for cardiovascular and diabetes risk prediction. Smit AJ, van de Zande SC, Mulder DJ. Curr Opin Nephrol Hypertens. 2022;31(6):522-526. doi:10.1097/MNH.0000000000000835

29. Skin autofluorescence increases postprandially in human subjects. Stirban A, Nandrean S, Negrean M, Koschinsky T, Tschoepe D. Diabetes Technol Ther. 2008;10(3):200-205. doi:10.1089/dia.2007.0275

30. The relationship of skin autofluorescence with diastolic function and HFA-PEFF score in a general population of older people. Teren M, Schott A, Sedding D, et al. Nutr Metab Cardiovasc Dis. Published online April 29, 2022:S0939-4753(22)00179-X. doi:10.1016/j.numecd.2022.04.008

31. A physically active lifestyle is related to a lower level of skin autofluorescence in a large population with chronic-disease (LifeLines cohort). Van de Zande SC, de Vries JK, van den Akker-Scheek I, Zwerver J, Smit AJ. J Sport Health Sci. Published online September 26, 2020:S2095-2546(20)30123-X. doi:10.1016/j.jshs.2020.09.007

32. Advanced Glycation End Product (AGE) Accumulation in the Skin is Associated with Depression: The Maastricht Study. Van Dooren FEP, Pouwer F, Schalkwijk CG, et al. Depress Anxiety. 2017;34(1):59-67. doi:10.1002/da.22527

33. Skin autofluorescence predicts incident type 2 diabetes, cardiovascular disease and mortality in the general population. Van Waateringe RP, Fokkens BT, Slagter SN, et al. Diabetologia. 2019;62(2):269-280. doi:10.1007/s00125-018-4769-x

34. The association between various smoking behaviors, cotinine biomarkers and skin autofluorescence, a marker for advanced glycation end product accumulation. Van Waateringe RP, Mook-Kanamori MJ, Slagter SN, et al. PLoS One. 2017;12(6):e0179330. doi:10.1371/journal.pone.0179330

35. Skin autofluorescence, a non-invasive biomarker for advanced glycation end products, is associated with the metabolic syndrome and its individual components. Van Waateringe RP, Slagter SN, van Beek AP, et al. Diabetol Metab Syndr. 2017;9:42. doi:10.1186/s13098-017-0241-1

36. Lifestyle and clinical determinants of skin autofluorescence in a population-based cohort study. Van Waateringe RP, Slagter SN, van der Klauw MM, et al. Eur J Clin Invest. 2016;46(5):481-490. doi:10.1111/eci.12627

37. Ethnicity and skin autofluorescence-based risk-engines for cardiovascular disease and diabetes mellitus. Ahmad MS, Kimhofer T, Ahmad S, et al. PLoS One. 2017;12(9):e0185175. doi:10.1371/journal.pone.0185175

38. Clinical significance of skin autofluorescence for diabetic macroangiopathy and comparison with conventional markers of atherosclerosis: a cross-sectional and prospective study. Aoki E, Hirashima T, Kumamoto Y, et al. Diabetol Int. 2023;14(2):145-154. doi:10.1007/s13340-022-00608-8

39. Association between small fiber neuropathy and higher skin accumulation of advanced glycation end products in patients with type 1 diabetes. Araszkiewicz A, Gandecka A, Nowicki M, et al. Pol Arch Med Wewn. 2016;126(11):847-853. doi:10.20452/pamw.3649

40. Increased accumulation of skin advanced glycation end products is associated with microvascular complications in type 1 diabetes. Araszkiewicz A, Naskret D, Niedzwiecki P, Samborski P, Wierusz-Wysocka B, Zozulinska-Ziolkiewicz D. Diabetes Technol Ther. 2011;13(8):837-842. doi:10.1089/dia.2011.0043

41. Skin autofluorescence is associated with carotid intima-media thickness, diabetic microangiopathy, and long-lasting metabolic control in type 1 diabetic patients. Results from Poznan Prospective Study. Araszkiewicz A, Naskret D, Zozulinska-Ziolkiewicz D, et al. Microvasc Res. 2015;98:62-67. doi:10.1016/j.mvr.2015.01.002

42. In diabetic Charcot neuroarthropathy impaired microvascular function is related to long lasting metabolic control and low grade inflammatory process. Araszkiewicz A, Soska J, Borucka K, et al. Microvasc Res. 2015;101:143-147. doi:10.1016/j.mvr.2015.07.008

43. Advanced glycation end products (AGEs) and the soluble receptor for AGE (sRAGE) in patients with type 1 diabetes and coeliac disease. Bakker SF, Tushuizen ME, Gözütok E, et al. Nutr Metab Cardiovasc Dis. 2015;25(2):230-235. doi:10.1016/j.numecd.2014.10.009

44. Advanced glycation end products, measured in skin, vs. HbA1c in children with type 1 diabetes mellitus. Banser A, Naafs JC, Hoorweg-Nijman JJ, van de Garde EM, van der Vorst MM. Pediatr Diabetes. 2016;17(6):426-432. doi:10.1111/pedi.12311

45. Skin autofluorescence, renal insufficiency and retinopathy in patients with type 2 diabetes. Bentata R, Cougnard-Grégoire A, Delyfer MN, et al. J Diabetes Complications. 2017;31(3):619-623. doi:10.1016/j.jdiacomp.2016.10.028

46. Advanced glycation end-products, measured as skin autofluorescence, associate with vascular stiffness in diabetic, pre-diabetic and normoglycemic individuals: a cross-sectional study. Birukov A, Cuadrat R, Polemiti E, Eichelmann F, Schulze MB. Cardiovasc Diabetol. 2021;20(1):110. doi:10.1186/s12933-021-01296-5

47. Skin autofluorescence predicts major adverse cardiovascular events in patients with type 1 diabetes: a 7-year follow-up study. Blanc-Bisson C, Velayoudom-Cephise FL, Cougnard-Gregoire A, et al. Cardiovasc Diabetol. 2018;17(1):82. doi:10.1186/s12933-018-0718-8

48. A non-invasive risk score including skin autofluorescence predicts diabetes risk in the general population. Boersma HE, van der Klauw MM, Smit AJ, Wolffenbuttel BHR. Sci Rep. 2022;12(1):21794. doi:10.1038/s41598-022-26313-9

49. Skin autofluorescence predicts new cardiovascular disease and mortality in people with type 2 diabetes. Boersma HE, van Waateringe RP, van der Klauw MM, et al. BMC Endocr Disord. 2021;21(1):14. doi:10.1186/s12902-020-00676-4

50. The skin autofluorescence of advanced glycation end-products relates to the development of foot ulcers in type 2 diabetes: A longitudinal observational study. Borderie G, Foussard N, Larroumet A, et al. Journal of Diabetes and its Complications. 2023;37(10):108595. doi:10.1016/j.jdiacomp.2023.108595

51. Advanced glycation end products, measured as skin autofluorescence and diabetes complications: a systematic review. Bos DC, de Ranitz-Greven WL, de Valk HW. Diabetes Technol Ther. 2011;13(7):773-779. doi:10.1089/dia.2011.0034

52. Skin Autofluorescence-Indicated Advanced Glycation End Products as Predictors of Cardiovascular and All-Cause Mortality in High-Risk Subjects: A Systematic Review and Meta-analysis. Cavero-Redondo I, Soriano-Cano A, Álvarez-Bueno C, et al. J Am Heart Assoc. 2018;7(18):e009833. doi:10.1161/JAHA.118.009833

53. Advanced glycation end products assessed by skin autofluorescence in type 1 diabetics are associated with nephropathy, but not retinopathy. Chabroux S, Canouï-Poitrine F, Reffet S, et al. Diabetes Metab. 2010;36(2):152-157. doi:10.1016/j.diabet.2009.11.003

54. Higher skin autofluorescence in young people with Type 1 diabetes and microvascular complications. Cho YH, Craig ME, Januszewski AS, et al. Diabet Med. 2017;34(4):543-550. doi:10.1111/dme.13280

55. Skin accumulation of advanced glycation end products and cardiovascular risk in Korean patients with type 2 diabetes mellitus. Choi LS, Ahmed K, Kim YS, Yim JE. Heliyon. 2022;8(6):e09571. doi:10.1016/j.heliyon.2022.e09571

56. Gradual increase in advanced glycation end-products from no diabetes to early and regular gestational diabetes: A case-control study. Cosson E, Gary F, Nguyen MT, et al. Diabetes Metab. 2019;45(6):586-589. doi:10.1016/j.diabet.2018.01.007

57. Achilles tendons in people with type 2 diabetes show mildly compromised structure: an ultrasound tissue characterisation study. De Jonge S, Rozenberg R, Vieyra B, et al. Br J Sports Med. 2015;49(15):995-999. doi:10.1136/bjsports-2014-093696

58. Advanced glycation end products, measured as skin autofluorescence, at diagnosis in gestational diabetes mellitus compared with normal pregnancy. De Ranitz-Greven WL, Bos DC, Poucki WK, et al. Diabetes Technol Ther. 2012;14(1):43-49. doi:10.1089/dia.2011.0105

59. Advanced glycation end products, measured as skin autofluorescence, during normal pregnancy and pregnancy complicated by diabetes mellitus. De Ranitz-Greven WL, Kaasenbrood L, Poucki WK, et al. Diabetes Technol Ther. 2012;14(12):1134-1139. doi:10.1089/dia.2012.0120

60. Advanced glycation end products measured by skin autofluorescence in a population with central obesity. Den Engelsen C, van den Donk M, Gorter KJ, Salomé PL, Rutten GE. Dermatoendocrinol. 2012;4(1):33-38. doi:10.4161/derm.17999

61. Risk factors for autonomic and somatic nerve dysfunction in different stages of glucose tolerance. Dimova R, Tankova T, Guergueltcheva V, et al. J Diabetes Complications. 2017;31(3):537-543. doi:10.1016/j.jdiacomp.2016.11.002

62. Study design of DIACORE (DIAbetes COhoRtE) – a cohort study of patients with diabetes mellitus type 2. Dörhöfer L, Lammert A, Krane V, et al. BMC Med Genet. 2013;14:25. doi:10.1186/1471-2350-14-25

63. Within- and Between-Body-Site Agreement of Skin Autofluorescence Measurements in People With and Without Diabetes-Related Foot Disease. Fernando ME, Crowther RG, Lazzarini PA, et al. J Diabetes Sci Technol. 2019;13(5):836-846. doi:10.1177/1932296819853555

64. Skin Autofluorescence is an Independent Predictor of Post Stroke Infection in Diabetes. Filipov A, Fuchshuber H, Kraus J, Ebert AD, Sandikci V, Alonso A. J Stroke Cerebrovasc Dis. 2021;30(9):105949. doi:10.1016/j.jstrokecerebrovasdis.2021.105949

65. Measuring of Advanced Glycation End Products in Acute Stroke Care: Skin Autofluorescence as a Predictor of Ischemic Stroke Outcome in Patients with Diabetes Mellitus. Filipov A, Fuchshuber H, Kraus J, Ebert AD, Sandikci V, Alonso A.J Clin Med. 2022;11(6):1625. doi:10.3390/jcm11061625

66. Skin autofluorescence improves the Finnish Diabetes Risk Score in the detection of diabetes in a large population-based cohort: The LifeLines Cohort Study. Fokkens BT, van Waateringe RP, Mulder DJ, Wolffenbuttel BHR, Smit AJ. Diabetes Metab. 2018;44(5):424-430. doi:10.1016/j.diabet.2017.09.002

67. Vitreous advanced glycation endproducts and α-dicarbonyls in retinal detachment patients with type 2 diabetes mellitus and non-diabetic controls. Fokkens BT, Mulder DJ, Schalkwijk CG, Scheijen JL, Smit AJ, Los LI. PLoS One. 2017;12(3):e0173379. doi:10.1371/journal.pone.0173379

68. Skin fluorescence as a clinical tool for non-invasive assessment of advanced glycation and long-term complications of diabetes. Fokkens BT, Smit AJ. Glycoconj J. 2016;33(4):527-535. doi:10.1007/s10719-016-9683-1

69. Skin autofluorescence predicts cancer in subjects with type 2 diabetes. Foussard N, Larroumet A, Rigo M, et al. BMJ Open Diabetes Res Care. 2021;9(1):e001312. doi:10.1136/bmjdrc-2020-001312

70. Potential inhibitory effects of L-carnitine supplementation on tissue advanced glycation end products in patients with hemodialysis. Fukami K, Yamagishi SI, Sakai K, et al. Rejuvenation Res. 2013;16(6):460-466. doi:10.1089/rej.2013.1459

71. Advanced Glycation Endproducts and Bone Material Strength in Type 2 Diabetes. Furst JR, Bandeira LC, Fan WW, et al. J Clin Endocrinol Metab. 2016;101(6):2502-2510. doi:10.1210/jc.2016-1437

72. Skin autofluorescence is associated with past glycaemic control and complications in type 1 diabetes mellitus. Genevieve M, Vivot A, Gonzalez C, et al. Diabetes Metab. 2013;39(4):349-354. doi:10.1016/j.diabet.2013.03.003

73. Skin autofluorescence: a tool to identify type 2 diabetic patients at risk for developing microvascular complications. Gerrits EG, Lutgers HL, Kleefstra N, et al. Diabetes Care. 2008;31(3):517-521. doi:10.2337/dc07-1755

74. Association of Advanced Glycation End Products with coronary Artery Calcification in Japanese Subjects with Type 2 Diabetes as Assessed by Skin Autofluorescence. Hangai M, Takebe N, Honma H, et al. J Atheroscler Thromb. 2016;23(10):1178-1187. doi:10.5551/jat.30155

75. The relationship between advanced glycation end products and ocular circulation in type 2 diabetes. Hashimoto K, Kunikata H, Yasuda M, et al. J Diabetes Complications. 2016;30(7):1371-1377. doi:10.1016/j.jdiacomp.2016.04.024

76. Time-varying parameters of glycemic control and glycation in relation to arterial stiffness in patients with type 1 diabetes. Helleputte S, Calders P, Rodenbach A, et al. Cardiovasc Diabetol. 2022;21:277. doi:10.1186/s12933-022-01717-z

77. Correlation between diabetic retinopathy severity and elevated skin autofluorescence as a marker of advanced glycation end-product accumulation in type 2 diabetic patients. Hirano T, Iesato Y, Toriyama Y, Imai A, Chiba D, Murata T. J Diabetes Complications. 2014;28(5):729-734. doi:10.1016/j.jdiacomp.2014.03.003

78. Elevated skin autofluorescence is strongly associated with foot ulcers in patients with diabetes: a cross-sectional, observational study of Chinese subjects. Hu H, Han C mao, Hu X lei, Ye W lan, Huang W juan, Smit AJ. J Zhejiang Univ Sci B. 2012;13(5):372-377. doi:10.1631/jzus.B1100249

79. AGEs and chronic subclinical inflammation in diabetes: disorders of immune system. Hu H, Jiang H, Ren H, Hu X, Wang X, Han C. Diabetes Metab Res Rev. 2015;31(2):127-137. doi:10.1002/dmrr.2560

80. Non-invasive measures of tissue autofluorescence are increased in Type 1 diabetes complications and correlate with a non-invasive measure of vascular dysfunction. Januszewski AS, Sachithanandan N, Karschimkus C, et al. Diabet Med. 2012;29(6):726-733. doi:10.1111/j.1464-5491.2011.03562.x

81. Skin autofluorescence is associated with higher risk of cardiovascular events in Chinese adults with type 2 diabetes: A prospective cohort study from the Hong Kong Diabetes Biobank. Jin Q, Lau ESH, Luk AOY, et al. J Diabetes Complications. 2021;35(10):108015. doi:10.1016/j.jdiacomp.2021.108015

82. Skin autofluorescence is associated with progression of kidney disease in type 2 diabetes: A prospective cohort study from the Hong Kong diabetes biobank. Nutrition, Metabolism and Cardiovascular Diseases. Jin Q, Lau ES, Luk AO, et al. 2021;0(0). doi:10.1016/j.numecd.2021.10.007

83. Therapeutic options to reduce advanced glycation end products in patients with diabetes mellitus: A review. Jud P, Sourij H. Diabetes Res Clin Pract. 2019;148:54-63. doi:10.1016/j.diabres.2018.11.016

84. Erectile Dysfunction in Individuals with Type 1 Diabetes is Associated with Long-term Metabolic Control and Diabetic Complications: A Cross-Sectional Study. Kaminski M, Kulecki M, Lachowski P, et al. Int J Angiol. 2022;31(2):97-106. doi:10.1055/s-0041-1735209

85. Advanced glycation end products in infant formulas do not contribute to insulin resistance associated with their consumption. Klenovics KS, Boor P, Somoza V, Celec P, Fogliano V, Sebeková K. PLoS One. 2013;8(1):e53056. doi:10.1371/journal.pone.0053056

86. Skin autofluorescence (a marker for advanced glycation end products) and erectile dysfunction in diabetes. Kouidrat Y, Zaitouni A, Amad A, et al. J Diabetes Complications. 2017;31(1):108-113. doi:10.1016/j.jdiacomp.2016.10.026

87. Vitamin D status is associated with skin autofluorescence in patients with type 2 diabetes mellitus: a preliminary report. Krul-Poel YHM, Agca R, Lips P, van Wijland H, Stam F, Simsek S. Cardiovasc Diabetol. 2015;14:89. doi:10.1186/s12933-015-0250-z

88. The relationship between circulating irisin levels and tissues AGE accumulation in type 2 diabetes patients. Li Z, Wang G, Zhu YJ, et al. Biosci Rep. 2017;37(3):BSR20170213. doi:10.1042/BSR20170213

89. The association between skin autofluorescence and vascular complications in Chinese patients with diabetic foot ulcer: an observational study done in Shanghai. Liu C, Xu L, Gao H, et al. Int J Low Extrem Wounds. 2015;14(1):28-36. doi:10.1177/1534734614568375

90. Advanced glycation end products are associated with arterial stiffness in type 1 diabetes. Llauradó G, Ceperuelo-Mallafré V, Vilardell C, et al. J Endocrinol. 2014;221(3):405-413. doi:10.1530/JOE-13-0407

91. Skin autofluorescence provides additional information to the UK Prospective Diabetes Study (UKPDS) risk score for the estimation of cardiovascular prognosis in type 2 diabetes mellitus. Lutgers HL, Gerrits EG, Graaff R, et al. Diabetologia. 2009;52(5):789-797. doi:10.1007/s00125-009-1308-9

92. Skin Autofluorescence as a Noninvasive Marker of Vascular Damage in Patients With Type 2 Diabetes. Lutgers HL, Graaff R, Links TP, et al. Diabetes Care. 2006;29(12):2654-2659. doi:10.2337/dc05-2173

93. Skin autofluorescence measurement in the clinical practice of diabetology and nephrology. Mácsai E. Orv Hetil. 2012;153(42):1651-1657. doi:10.1556/OH.2012.29453

94. Correlations between skin autofluorescence and conventional glycemic markers in patients with diabetes. Mácsai E, Rakk E, Miléder M, Fulcz Á. Orv Hetil. 2015;156(33):1341-1347. doi:10.1556/650.2015.30229

95. Verification of skin autofluorescence values by mass spectrometry in adolescents with type 1 diabetes: brief report. Mácsai E, Takáts Z, Derzbach L, Körner A, Vásárhelyi B. Diabetes Technol Ther. 2013;15(3):269-272. doi:10.1089/dia.2012.0251

96. The Fast-Glycator Phenotype, Skin Advanced Glycation End Products, and Complication Burden Among People With Type 1 Diabetes. Maran A, Morieri ML, Falaguasta D, Avogaro A, Fadini GP. Diabetes Care. Published online August 15, 2022:dc220980. doi:10.2337/dc22-0980

97. Non-invasive skin autofluorescence as a screening method for diabetic retinopathy. Diabetes Metab Res Rev. Martínez-García I, Cavero-Redondo I, Álvarez-Bueno C, Pascual-Morena C, Gómez-Guijarro MD, Saz-Lara A. Published online September 6, 2023:e3721. doi:10.1002/dmrr.3721

98. Is skin autofluorescence a marker of metabolic memory in pregnant women with diabetes? Maury E, Savel J, Grouthier V, et al. Diabet Med. 2015;32(12):1575-1579. doi:10.1111/dme.12803

99. Increased accumulation of skin advanced glycation end-products precedes and correlates with clinical manifestation of diabetic neuropathy. Meerwaldt R, Links TP, Graaff R, et al. Diabetologia. 2005;48(8):1637-1644. doi:10.1007/s00125-005-1828-x

100. Skin autofluorescence is a strong predictor of cardiac mortality in diabetes. Meerwaldt R, Lutgers HL, Links TP, et al. Diabetes Care. 2007;30(1):107-112. doi:10.2337/dc06-1391

101. Skin autofluorescence in type 2 diabetes: beyond blood glucose. Monami M, Lamanna C, Gori F, Bartalucci F, Marchionni N, Mannucci E. Diabetes Res Clin Pract. 2008;79(1):56-60. doi:10.1016/j.diabres.2007.07.007

102. Skin collagen advanced glycation endproducts (AGEs) and the long-term progression of sub-clinical cardiovascular disease in type 1 diabetes. Monnier VM, Sun W, Gao X, et al. Cardiovasc Diabetol. 2015;14:118. doi:10.1186/s12933-015-0266-4

103. Type 2 diabetes, skin autofluorescence, and brain atrophy. Diabetes. Moran C, Münch G, Forbes JM, et al. 2015;64(1):279-283. doi:10.2337/db14-0506

104. Advanced glycation end-products are a risk for muscle weakness in Japanese patients with type 1 diabetes. Mori H, Kuroda A, Araki M, et al. J Diabetes Investig. 2017;8(3):377-382. doi:10.1111/jdi.12582

105. Skin autofluorescence is inversely related to HDL anti-oxidative capacity in type 2 diabetes mellitus. Mulder DJ, de Boer JF, Graaff R, et al. Atherosclerosis. 2011;218(1):102-106. doi:10.1016/j.atherosclerosis.2011.05.011

106. Skin autofluorescence and risk of micro- and macrovascular complications in patients with Type 2 diabetes mellitus-a multi-centre study. Noordzij MJ, Mulder DJ, Oomen PHN, et al. Diabet Med. 2012;29(12):1556-1561. doi:10.1111/dme.12005

107. Skin Autofluorescence is Associated with Early-stage Atherosclerosis in Patients with Type 1 Diabetes. Osawa S, Katakami N, Kuroda A, et al. J Atheroscler Thromb. 2017;24(3):312-326. doi:10.5551/jat.35592

108. Skin autofluorescence is associated with vascular complications in patients with type 2 diabetes. Osawa S, Katakami N, Sato I, et al. J Diabetes Complications. 2018;32(9):839-844. doi:10.1016/j.jdiacomp.2018.06.009

109. Correlation between skin advanced glycation end products and cardiac autonomic neuropathy among subjects with type 2 diabetes mellitus. Papachristou S, Pafili K, Trypsianis G, Papazoglou D, Vadikolias K, Papanas N. Exp Clin Endocrinol Diabetes. Published online April 21, 2022. doi:10.1055/a-1831-0991

110. Skin AGEs and diabetic neuropathy. Papachristou S, Pafili K, Papanas N. BMC Endocr Disord. 2021;21(1):28. doi:10.1186/s12902-021-00697-7

111. Skin Advanced Glycation End Products among Subjects with Type 2 Diabetes Mellitus with or without Distal Sensorimotor Polyneuropathy. Papachristou S, Pafili K, Trypsianis G, Papazoglou D, Vadikolias K, Papanas N. J Diabetes Res. 2021;2021:6045677. doi:10.1155/2021/6045677

112. Usefulness of skin advanced glycation end products to predict coronary artery calcium score in patients with type 2 diabetes. Planas A, Simó-Servat O, Bañeras J, et al. Acta Diabetol. 2021;58(10):1403-1412. doi:10.1007/s00592-021-01735-5

113. Advanced Glycations End Products in the Skin as Biomarkers of Cardiovascular Risk in Type 2 Diabetes. Planas A, Simó-Servat O, Hernández C, Simó R. Int J Mol Sci. 2022;23(11):6234. doi:10.3390/ijms23116234

114. The Bright Side of Skin Autofluorescence Determination in Children and Adolescents with Newly Diagnosed Type 1 Diabetes Mellitus: A Potential Predictor of Remission? Podolakova K, Barak L, Jancova E, Stanik J, Sebekova K, Podracka L. International Journal of Environmental Research and Public Health. 2022;19(19):11950. doi:10.3390/ijerph191911950

115. Advanced glycation end products and diabetic cardiovascular disease. Prasad A, Bekker P, Tsimikas S. Cardiol Rev. 2012;20(4):177-183. doi:10.1097/CRD.0b013e318244e57c

116. Skin autofluorescence and peripheral neuropathy four years later in type 1 diabetes. Rajaobelina K, Farges B, Nov S, et al. Diabetes Metab Res Rev. 2017;33(2). doi:10.1002/dmrr.2832

117. Autofluorescence of Skin Advanced Glycation End Products: Marker of Metabolic Memory in Elderly Population. Rajaobelina K, Cougnard-Gregoire A, Delcourt C, Gin H, Barberger-Gateau P, Rigalleau V. J Gerontol A Biol Sci Med Sci. 2015;70(7):841-846. doi:10.1093/gerona/glu243

118. Progression of skin autofluorescence of AGEs over 4 years in patients with type 1 diabetes. Rajaobelina K, Helmer C, Vélayoudom-Céphise FL, et al. Diabetes Metab Res Rev. 2017;33(7). doi:10.1002/dmrr.2917

119. Association of advanced glycation end products and chronic kidney disease with macroangiopathy in type 2 diabetes. Rigalleau V, Cougnard-Gregoire A, Nov S, et al. J Diabetes Complications. 2015;29(2):270-274. doi:10.1016/j.jdiacomp.2014.10.011

120. Cardiovascular events after a dramatic reduction of HbA1c in hospitalized subjects with type 2 diabetes and high long-term glucose exposure. Rigalleau V, Larroumet A, Ducos C, et al. J Diabetes Complications. Published online June 21, 2022:108234. doi:10.1016/j.jdiacomp.2022.108234

121. Skin autofluorescence, a marker of glucose memory in type 2 diabetes. Rigo M, Lecocq M, Brouzeng C, et al. Metabol Open. 2020;7:100038. doi:10.1016/j.metop.2020.100038

122. Increased skin autofluorescence of advanced glycation end products (AGEs) in subjects with cardiovascular risk factors. Sakly R, Wolffenbuttel BHR, Khochtali I, et al. Int J Diabetes Dev Ctries. Published online August 2, 2022. doi:10.1007/s13410-022-01121-z

123. Advanced Glycation End Products: New Clinical and Molecular Perspectives. Salazar J, Navarro C, Ortega Á, et al. Int J Environ Res Public Health. 2021;18(14):7236. doi:10.3390/ijerph18147236

124. Assessment of skin autofluorescence as a marker of advanced glycation end product accumulation in type 1 diabetes. Samborski P, Naskret D, Araszkiewicz A, Niedzwiecki P, Zozulinska-Ziólkiewicz D, Wierusz-Wysocka B.Pol Arch Med Wewn. 2011;121(3):67-72.

125. Skin autofluorescence relates to soluble receptor for advanced glycation end-products and albuminuria in diabetes mellitus. Skrha J, Soupal J, Loni Ekali G, et al. J Diabetes Res. 2013;2013:650694. doi:10.1155/2013/650694

126. Skin autofluorescence corresponds to microvascular reactivity in diabetes mellitus. J Diabetes Complications. Škrha J, Horová E, Šoupal J, et al. Published online April 28, 2022:108206. doi:10.1016/j.jdiacomp.2022.108206

127. The clinical relevance of advanced glycation endproducts (AGE) and recent developments in pharmaceutics to reduce AGE accumulation. Smit AJ, Lutgers HL. Curr Med Chem. 2004;11(20):2767-2784. doi:10.2174/0929867043364342

128. Skin autofluorescence based decision tree in detection of impaired glucose tolerance and diabetes. Smit AJ, Smit JM, Botterblom GJ, Mulder DJ. PLoS One. 2013;8(6):e65592. doi:10.1371/journal.pone.0065592

129. Vascular effects of advanced glycation endproducts: Clinical effects and molecular mechanisms. Stirban A, Gawlowski T, Roden M. Mol Metab. 2014;3(2):94-108. doi:10.1016/j.molmet.2013.11.006

130. Skin Autofluorescence – A Non-invasive Measurement for Assessing Cardiovascular Risk and Risk of Diabetes. Stirban A, Heinemann L. Eur Endocrinol. 2014;10(2):106-110. doi:10.17925/EE.2014.10.02.106

131. Evaluation of Relevance between Advanced Glycation End Products and Diabetic Retinopathy Stages Using Skin Autofluorescence. Takayanagi Y, Yamanaka M, Fujihara J, et al. Antioxidants (Basel). 2020;9(11):1100. doi:10.3390/antiox9111100

132. Skin autofluorescence is associated with severity of vascular complications in Japanese patients with Type 2 diabetes. Tanaka K, Tani Y, Asai J, et al. Diabet Med. 2012;29(4):492-500. doi:10.1111/j.1464-5491.2011.03448.x

133. Skin Autofluorescence as a Novel and Noninvasive Technology for Advanced Glycation End Products in Diabetic Foot Ulcers: A Systematic Review and Meta-analysis. Varikasuvu SR, Varshney S, Sulekar H. Adv Skin Wound Care. 2021;34(11):1-8. doi:10.1097/01.ASW.0000792932.01773.d5

134. Skin autofluorescence predicts cardio-renal outcome in type 1 diabetes: a longitudinal study. Vélayoudom-Céphise FL, Rajaobelina K, Helmer C, et al. Cardiovasc Diabetol. 2016;15(1):127. doi:10.1186/s12933-016-0448-8

135. Skin autofluorescence is increased in young people with type 1 diabetes exposed to secondhand smoking. Vollenbrock CE, Van Waateringe RP, Veeze HJ, Aanstoot HJ, Wolffenbuttel BHR. J Diabetes. 2017;9(3):308-310. doi:10.1111/1753-0407.12498

136. Advanced glycation end products assessed by skin autofluorescence: a new marker of diabetic foot ulceration. Vouillarmet J, Maucort-Boulch D, Michon P, Thivolet C. Diabetes Technol Ther. 2013;15(7):601-605. doi:10.1089/dia.2013.0009

137. Skin Autofluorescence Is Associated with Diabetic Peripheral Neuropathy in Chinese Patients with Type 2 Diabetes: A Cross-Sectional Study. Wan L, Qin G, Yan W, Sun T. Genet Test Mol Biomarkers. 2019;23(6):387-392. doi:10.1089/gtmb.2018.0328

138. Tissue advanced glycation end products are associated with diastolic function and aerobic exercise capacity in diabetic heart failure patients. Willemsen S, Hartog JWL, Hummel YM, et al. Eur J Heart Fail. 2011;13(1):76-82. doi:10.1093/eurjhf/hfq168

139. Relationship of skin autofluorescence to severity of retinopathy in type 2 diabetes. Yasuda M, Shimura M, Kunikata H, et al. Curr Eye Res. 2015;40(3):338-345. doi:10.3109/02713683.2014.918152

140. Skin Autofluorescence is a Noninvasive Surrogate Marker for Diabetic Microvascular Complications and Carotid Intima-Media Thickness in Japanese Patients with Type 2 Diabetes: A Cross-sectional Study. Yoshioka K. Diabetes Ther. 2018;9(1):75-85. doi:10.1007/s13300-017-0339-3

141. Accumulation of advanced glycation end products is associated with macrovascular events and glycaemic control with microvascular complications in Type 2 diabetes mellitus. Yozgatli K, Lefrandt JD, Noordzij MJ, et al. Diabet Med. Published online April 23, 2018. doi:10.1111/dme.13651

142. Correlation between the accumulation of skin glycosylation end products and the development of type 2 diabetic peripheral neuropathy. Zhao XW, Yue WX, Zhang SW, Chen Q. BMC Endocr Disord. 2022;22:106. doi:10.1186/s12902-022-00997-6

143. Decreased serum carnitine is independently correlated with increased tissue accumulation levels of advanced glycation end products in haemodialysis patients. Adachi T, Fukami K, Yamagishi SI, et al. Nephrology (Carlton). 2012;17(8):689-694. doi:10.1111/j.1440-1797.2012.01642.x

144. Skin autofluorescence profile in Tunisian hemodialysis patients with and without heart failure. Aloui S, Ajimi K, Hamouda M, et al. Published online November 22, 2021. doi:10.21203/rs.3.rs-900707/v1

145. Does hepatitis C increase the accumulation of advanced glycation end products in haemodialysis patients? Arsov S, Graaff R, Morariu AM, et al. Nephrol Dial Transplant. 2010;25(3):885-891. doi:10.1093/ndt/gfp564

146. Advanced glycation end-products and skin autofluorescence in end-stage renal disease: a review. Arsov S, Graaff R, van Oeveren W, et al. Clin Chem Lab Med. 2014;52(1):11-20. doi:10.1515/cclm-2012-0832

147. Advanced glycation end products (AGEs) estimated by skin autofluorescence are related with cardiovascular risk in renal transplant. Calviño J, Cigarran S, Gonzalez-Tabares L, et al. PLoS One. 2018;13(8):e0201118. doi:10.1371/journal.pone.0201118

148. Skin Autofluorescence-Indicated Advanced Glycation End Products as Predictors of Cardiovascular and All-Cause Mortality in High-Risk Subjects: A Systematic Review and Meta-analysis. Cavero-Redondo I, Soriano-Cano A, Álvarez-Bueno C, et al. J Am Heart Assoc. 2018;7(18):e009833. doi:10.1161/JAHA.118.009833

149. Tissue advanced glycation end product deposition after kidney transplantation. Crowley LE, Johnson CP, McIntyre N, et al. Nephron Clin Pract. 2013;124(1-2):54-59. doi:10.1159/000355692

150. Advanced glycation end products as predictors of renal function in youth with type 1 diabetes. Forbes JM, Le Bagge S, Righi S, et al. Sci Rep. 2021;11(1):9422. doi:10.1038/s41598-021-88786-4

151. Advanced glycation end-products (AGEs) accumulation in skin: relations with chronic kidney disease-mineral and bone disorder. França R de A, Esteves A de BA, Borges C de M, et al. J Bras Nefrol. 2017;39(3):253-260. doi:10.5935/0101-2800.20170042

152. Skin autofluorescence and all-cause mortality in stage 3 CKD. Fraser SDS, Roderick PJ, McIntyre NJ, et al. Clin J Am Soc Nephrol. 2014;9(8):1361-1368. doi:10.2215/CJN.09510913

153. Skin autofluorescence is a predictor of cardiovascular disease in chronic kidney disease patients. Furuya F, Shimura H, Takahashi K, et al. Ther Apher Dial. 2015;19(1):40-44. doi:10.1111/1744-9987.12204

154. Skin autofluorescence: a pronounced marker of mortality in hemodialysis patients. Gerrits EG, Lutgers HL, Smeets GHW, et al. Nephron Extra. 2012;2(1):184-191. doi:10.1159/000339282

155. AGEs, autofluorescence and renal function. Gerrits EG, Smit AJ, Bilo HJG. Nephrol Dial Transplant. 2009;24(3):710-713. doi:10.1093/ndt/gfn634

156. Skin and plasma autofluorescence during hemodialysis: a pilot study. Graaff R, Arsov S, Ramsauer B, et al.Artif Organs. 2014;38(6):515-518. doi:10.1111/aor.12205

157. Risk factors for chronic transplant dysfunction and cardiovascular disease are related to accumulation of advanced glycation end-products in renal transplant recipients. Hartog JWL, de Vries APJ, Bakker SJL, et al. Nephrol Dial Transplant. 2006;21(8):2263-2269. doi:10.1093/ndt/gfl132

158. Skin-autofluorescence is an independent predictor of graft loss in renal transplant recipients. Hartog JWL, Gross S, Oterdoom LH, et al. Transplantation. 2009;87(7):1069-1077. doi:10.1097/TP.0b013e31819d3173

159. Skin-autofluorescence, a measure of tissue advanced glycation end-products (AGEs), is related to diastolic function in dialysis patients. Hartog JWL, Hummel YM, Voors AA, et al. J Card Fail. 2008;14(7):596-602. doi:10.1016/j.cardfail.2008.03.008

160. Advanced glycation end products in kidney transplant patients: a putative role in the development of chronic renal transplant dysfunction. Hartog JWL, Smit AJ, van Son WJ, et al. Am J Kidney Dis. 2004;43(6):966-975. doi:10.1053/j.ajkd.2004.02.008

161. Impact of Dietetic Intervention on Skin Autofluorescence and Nutritional Status in Persons Receiving Dialysis: A Proof of Principle Study. Journal of Renal Nutrition. Hörner DV, Willingham FC, Selby NM, Taal MW. 2020;30(6):540-547. doi:10.1053/j.jrn.2019.12.006

162. Accumulation of tissue advanced glycation end products correlated with glucose exposure dose and associated with cardiovascular morbidity in patients on peritoneal dialysis. Jiang J, Chen P, Chen J, et al. Atherosclerosis. 2012;224(1):187-194. doi:10.1016/j.atherosclerosis.2012.06.022

163. Serum and Tissue Levels of Advanced Glycation End Products and Risk of Mortality in Patients on Maintenance Hemodialysis. Jiang J, Zhang Y, Chen J, et al. Am J Nephrol. 2021;52(1):8-16. doi:10.1159/000512385

164. Skin autofluorescence predicts cardiovascular mortality in patients on chronic hemodialysis. Kimura H, Tanaka K, Kanno M, et al. Ther Apher Dial. 2014;18(5):461-467. doi:10.1111/1744-9987.12160

165. Skin autofluorescence in acute kidney injury. Lavielle A, Rubin S, Boyer A, et al. Crit Care. 2017;21(1):24. doi:10.1186/s13054-017-1598-0

166. Plasma Catestatin Levels and Advanced Glycation End Products in Patients on Hemodialysis. Luketin M, Mizdrak M, Boric-Skaro D, et al. Biomolecules. 2021;11(3):456. doi:10.3390/biom11030456

167. Factors influencing skin autofluorescence of patients with peritoneal dialysis. Mácsai E, Benke A, Cseh A, Vásárhelyi B. Acta Physiol Hung. 2012;99(2):216-222. doi:10.1556/APhysiol.99.2012.2.15

168. Skin autofluorescence as a marker of cardiovascular risk in children with chronic kidney disease. Makulska I, Szczepanska M, Drozdz D, Polak-Jonkisz D, Zwolinska D. Pediatr Nephrol. 2013;28(1):121-128. doi:10.1007/s00467-012-2280-z

169. Skin autofluorescence as a novel marker of vascular damage in children and adolescents with chronic kidney disease. Makulska I, Szczepanska M, Drozdz D, Polak-Jonkisz D, Zwolinska D. Pediatr Nephrol. 2015;30(5):811-819. doi:10.1007/s00467-014-2997-y

170. Advanced glycation endproducts and dicarbonyls in end-stage renal disease: associations with uraemia and courses following renal replacement therapy. Martens RJH, Broers NJH, Canaud B, et al. Clin Kidney J. 2020;13(5):855-866. doi:10.1093/ckj/sfz099

171. Tissue-advanced glycation end product concentration in dialysis patients. McIntyre NJ, Chesterton LJ, John SG, et al. Clin J Am Soc Nephrol. 2010;5(1):51-55. doi:10.2215/CJN.05350709

172. Skin autofluorescence and the association with renal and cardiovascular risk factors in chronic kidney disease stage 3. McIntyre NJ, Fluck RJ, McIntyre CW, Taal MW. Clin J Am Soc Nephrol. 2011;6(10):2356-2363. doi:10.2215/CJN.02420311

173. Skin autofluorescence, a measure of cumulative metabolic stress and advanced glycation end products, predicts mortality in hemodialysis patients. Meerwaldt R, Hartog JWL, Graaff R, et al. J Am Soc Nephrol. 2005;16(12):3687-3693. doi:10.1681/ASN.2005020144

174. Tissue level of advanced glycation end products is an independent determinant of high-sensitivity C-reactive protein levels in haemodialysis patients. Nagano M, Fukami K, Yamagishi SI, et al. Nephrology (Carlton). 2011;16(3):299-303. doi:10.1111/j.1440-1797.2010.01419.x

175. Skin autofluorescence advanced glycosylation end products as an independent predictor of mortality in high flux haemodialysis and haemodialysis patients. Nongnuch A, Davenport A. Nephrology (Carlton). 2015;20(11):862-867. doi:10.1111/nep.12519

176. The Effect of On-Line Hemodiafiltration, Vegetarian Diet, and Urine Volume on Advanced Glycosylation End Products Measured by Changes in Skin Auto-Fluorescence. Nongnuch A, Davenport A. Artif Organs. 2018;42(11):1078-1085. doi:10.1111/aor.13143

177. Advanced glycation end products in renal failure: an overview. Noordzij MJ, Lefrandt JD, Smit AJ. J Ren Care. 2008;34(4):207-212. doi:10.1111/j.1755-6686.2008.00038.x

178. Evaluation of advanced glycation end products accumulation, using skin autofluorescence, in CKD and dialysis patients. Oleniuc M, Schiller A, Secara I, et al. Int Urol Nephrol. 2012;44(5):1441-1449. doi:10.1007/s11255-011-0097-5

179. Skin- and Plasma autofluorescence in hemodialysis with glucose-free or glucose-containing dialysate. Ramsauer B, Engels GE, Graaff R, Sikole A, Arsov S, Stegmayr B. BMC Nephrol. 2017;18(1):5. doi:10.1186/s12882-016-0418-0

180. Advanced oxidation protein products and advanced glycation end products in children and adolescents with chronic renal insufficiency. Sebeková K, Klenovicsová K, Ferenczová J, Hedvig J, Podracká L, Heidland A. J Ren Nutr. 2012;22(1):143-148. doi:10.1053/j.jrn.2011.10.022

181. The association of skin autofluorescence with cardiovascular events and all-cause mortality in persons with chronic kidney disease stage 3: A prospective cohort study. Shardlow A, McIntyre NJ, Kolhe NV, et al. PLoS Med. 2020;17(7):e1003163. doi:10.1371/journal.pmed.1003163

182. Tissue advanced glycation end products (AGEs), measured by skin autofluorescence, predict mortality in peritoneal dialysis. Siriopol D, Hogas S, Veisa G, et al. Int Urol Nephrol. 2015;47(3):563-569. doi:10.1007/s11255-014-0870-3

183. Skin autofluorescence as a measure of advanced glycation endproduct deposition: a novel risk marker in chronic kidney disease. Smit AJ, Gerrits EG. Curr Opin Nephrol Hypertens. 2010;19(6):527-533. doi:10.1097/MNH.0b013e32833e9259

184. Progress in risk prediction for people with chronic kidney disease. Taal MW. Curr Opin Nephrol Hypertens. 2014;23(6):519-524. doi:10.1097/MNH.0000000000000072

185. Skin autofluorescence is associated with the progression of chronic kidney disease: a prospective observational study. Tanaka K, Nakayama M, Kanno M, et al. PLoS One. 2013;8(12):e83799. doi:10.1371/journal.pone.0083799

186. Skin autofluorescence is associated with renal function and cardiovascular diseases in pre-dialysis chronic kidney disease patients. Tanaka K, Tani Y, Asai J, et al. Nephrol Dial Transplant. 2011;26(1):214-220. doi:10.1093/ndt/gfq369

187. Non-invasive Measurement of Skin Autofluorescence as a Beneficial Surrogate Marker for Atherosclerosis in Patients with Type 2 Diabetes. Temma J, Matsuhisa M, Horie T, et al. J Med Invest. 2015;62(3-4):126-129. doi:10.2152/jmi.62.126

188. Advanced glycation end products, carotid atherosclerosis, and circulating endothelial progenitor cells in patients with end-stage renal disease. Ueno H, Koyama H, Fukumoto S, et al. Metabolism. 2011;60(4):453-459. doi:10.1016/j.metabol.2010.04.001

189. Skin autofluorescence, a marker for advanced glycation end product accumulation, is associated with arterial stiffness in patients with end-stage renal disease.Ueno H, Koyama H, Tanaka S, et al. Metabolism. 2008;57(10):1452-1457. doi:10.1016/j.metabol.2008.05.016

190. Impact of a medium cut-off dialyzer on skin autofluorescence in haemodialysis patients. Viramontes Horner D, Kolhe N, Leung J, Fluck R, Selby N, Taal M. Nephrology Dialysis Transplantation. 2020;35(Supplement_3). doi:10.1093/ndt/gfaa142.P1078

191. Factors Associated With Change in Skin Autofluorescence, a Measure of Advanced Glycation End Products, in Persons Receiving Dialysis. Viramontes Hörner D, Selby NM, Taal MW. Kidney Int Rep. 2020;5(5):654-662. doi:10.1016/j.ekir.2020.02.003

192. Skin autofluorescence and malnutrition as predictors of mortality in persons receiving dialysis: a prospective cohort study. Viramontes Hörner D, Selby NM, Taal MW. J Hum Nutr Diet. 2020;33(6):852-861. doi:10.1111/jhn.12764

193. Skin autofluorescence: an emerging biomarker in persons with kidney disease. Viramontes Hörner D, Taal MW. Curr Opin Nephrol Hypertens. 2019;28(6):507-512. doi:10.1097/MNH.0000000000000549

194. Skin autofluorescence associates with vascular calcification in chronic kidney disease. Wang AYM, Wong CK, Yau YY, Wong S, Chan IHS, Lam CWK. Arterioscler Thromb Vasc Biol. 2014;34(8):1784-1790. doi:10.1161/ATVBAHA.114.303378

195. Skin autofluorescence is associated with rapid renal function decline in subjects at increased risk of coronary artery disease. Wang CC, Shen MY, Chang KC, Wang GJ, Liu SH, Chang CT. PLoS One. 2019;14(5):e0217203. doi:10.1371/journal.pone.0217203

196. Skin Autofluorescence Is Associated with Endothelial Dysfunction in Uremic Subjects on Hemodialysis. Wang CC, Wang YC, Wang GJ, et al. PLoS One. 2016;11(1):e0147771. doi:10.1371/journal.pone.0147771

197. Coronary artery calcification and aortic valve calcification in patients with kidney failure: a sex-disaggregated study. Ward LJ, Laucyte-Cibulskiene A, Hernandez L, et al. Biol Sex Differ. 2023;14(1):48. doi:10.1186/s13293-023-00530-x

198. Treatment of Diabetic Kidney Disease: Current and Future. Yamazaki T, Mimura I, Tanaka T, Nangaku M. Diabetes Metab J. 2021;45(1):11-26. doi:10.4093/dmj.2020.021

199. The Relationship Between Level of End-Products of Tissue Glycation and Pulse Wave Velocity in Non-diabetic Patients With Cardiovascular Disease. Ageev FT, Vitsenia MV, Smirnova MD, Mihailov GV. Kardiologiia. 2015;55(6):63-67. doi:10.18565/cardio.2015.6.63-67

200. Skin accumulation of advanced glycation end products is increased in patients with an abdominal aortic aneurysm. Boersema J, de Vos LC, Links TP, et al. J Vasc Surg. 2017;66(6):1696-1703.e1. doi:10.1016/j.jvs.2017.04.037

201. Skin Autofluorescence-Indicated Advanced Glycation End Products as Predictors of Cardiovascular and All-Cause Mortality in High-Risk Subjects: A Systematic Review and Meta-analysis. Cavero-Redondo I, Soriano-Cano A, Álvarez-Bueno C, et al. J Am Heart Assoc. 2018;7(18):e009833. doi:10.1161/JAHA.118.009833

202. Advanced glycation end products via skin autofluorescence as a new biomarker for major adverse cardiovascular events: A meta-analysis of prospective studies. Chen Q, Huang Q, Liu W, Zhou X. Nutr Metab Cardiovasc Dis. 2022;32(5):1083-1092. doi:10.1016/j.numecd.2022.01.032

203. Diverging effects of diabetes mellitus in patients with peripheral artery disease and abdominal aortic aneurysm and the role of advanced glycation end-products: ARTERY study – protocol for a multicentre cross-sectional study. De Vos LC, Boersema J, Hillebrands JL, et al. BMJ Open. 2017;7(4):e012584. doi:10.1136/bmjopen-2016-012584

204. Skin autofluorescence as a measure of advanced glycation end products deposition predicts 5-year amputation in patients with peripheral artery disease. De Vos LC, Boersema J, Mulder DJ, Smit AJ, Zeebregts CJ, Lefrandt JD. Arterioscler Thromb Vasc Biol. 2015;35(6):1532-1537. doi:10.1161/ATVBAHA.115.305407

205. Skin autofluorescence is associated with 5-year mortality and cardiovascular events in patients with peripheral artery disease. De Vos LC, Mulder DJ, Smit AJ, et al. Arterioscler Thromb Vasc Biol. 2014;34(4):933-938. doi:10.1161/ATVBAHA.113.302731

206. Skin autofluorescence as a measure of advanced glycation end products deposition is elevated in peripher al artery disease. De Vos LC, Noordzij MJ, Mulder DJ, et al. Arterioscler Thromb Vasc Biol. 2013;33(1):131-138. doi:10.1161/ATVBAHA.112.300016

207. Skin autofluorescence, a non-invasive marker for AGE accumulation, is associated with the degree of atherosclerosis. Den Dekker MAM, Zwiers M, van den Heuvel ER, et al. PLoS One. 2013;8(12):e83084. doi:10.1371/journal.pone.0083084

208. Advanced glycation end-products, anti-hypertensive treatment and diastolic function in patients with hypertension and diastolic dysfunction. Hartog JWL, van de Wal RM, Schalkwijk CG, et al. Eur J Heart Fail. 2010;12(4):397-403. doi:10.1093/eurjhf/hfq001

209. Clinical and prognostic value of advanced glycation end-products in chronic heart failure. Hartog JWL, Voors AA, Schalkwijk CG, et al. Eur Heart J. 2007;28(23):2879-2885. doi:10.1093/eurheartj/ehm486

210. Effects of alagebrium, an advanced glycation endproduct breaker, on exercise tolerance and cardiac function in patients with chronic heart failure. Hartog JWL, Willemsen S, van Veldhuisen DJ, et al. Eur J Heart Fail. 2011;13(8):899-908. doi:10.1093/eurjhf/hfr067

211. Impact of Hemorheology Assessed by the Microchannel Method on Pulsatility Index of the Common Carotid Artery in Patients With Type 2 Diabetes Mellitus. Hitsumoto T. J Clin Med Res. 2017;9(7):579-585. doi:10.14740/jocmr3031w

212. Skin Autofluorescence as a Predictor of First Heart Failure Hospitalization in Patients With Heart Failure With Preserved Ejection Fraction. Hitsumoto T. Cardiol Res. 2020;11(4):247-255. doi:10.14740/cr1097

213. Relationship between cardiac tissue glycation and skin autofluorescence in patients with coronary artery disease. Hofmann B, Jacobs K, Navarrete Santos A, Wienke A, Silber RE, Simm A. Diabetes Metab. 2015;41(5):410-415. doi:10.1016/j.diabet.2014.12.001

214. Advanced glycation end product associated skin autofluorescence: a mirror of vascular function? Hofmann B, Adam AC, Jacobs K, et al. Exp Gerontol. 2013;48(1):38-44. doi:10.1016/j.exger.2012.04.011

215. The skin autofluorescence reflects the posttranslational glycation grade of the matrix protein collagen. Jacobs K, Navarrete Santos A, Simm A, Silber RE, Hofmann B. Free Radic Biol Med. 2014;75 Suppl 1:S34. doi:10.1016/j.freeradbiomed.2014.10.772

216. Relation between food and drinking habits, and skin autofluorescence and intima media thickness in subjects at high cardiovascular risk. Jochemsen BM, Mulder DJ, van Doormaal JJ, et al. Journal of Food and Nutrition Research (Slovak Republic). Published online 2009. Accessed October 4, 2021.

217. Association between the tissue accumulation of advanced glycation end products and exercise capacity in cardiac rehabilitation patients. Kunimoto M, Shimada K, Yokoyama M, et al. BMC Cardiovasc Disord. 2020;20:195. doi:10.1186/s12872-020-01484-3

218. Relationship between skin autofluorescence levels and clinical events in patients with heart failure undergoing cardiac rehabilitation. Kunimoto M, Yokoyama M, Shimada K, et al. Cardiovasc Diabetol. 2021;20:208. doi:10.1186/s12933-021-01398-0

219. A Comparative Study on Skin and Plasma Advanced Glycation End Products and Their Associations with Arterial Stiffness. Liu CY, Huang QF, Cheng YB, et al. Pulse (Basel). 2017;4(4):208-218. doi:10.1159/000453581

220. Carotid artery intima media thickness associates with skin autofluoresence in non-diabetic subjects without clinically manifest cardiovascular disease. Lutgers HL, Graaff R, de Vries R, Smit AJ, Dullaart RPF. Eur J Clin Invest. 2010;40(9):812-817. doi:10.1111/j.1365-2362.2010.02329.x

221. Clinical relevance of advanced glycation endproducts for vascular surgery. Meerwaldt R, van der Vaart MG, van Dam GM, et al. Eur J Vasc Endovasc Surg. 2008;36(2):125-131. doi:10.1016/j.ejvs.2008.01.030

222. Skin autofluorescence is elevated in acute myocardial infarction and is associated with the one-year incidence of major adverse cardiac events. Mulder DJ, van Haelst PL, Graaff R, Gans RO, Zijlstra F, Smit AJ. Neth Heart J. 2009;17(4):162-168. doi:10.1007/BF03086239

223. Skin Autofluorescence is an independent marker for Acute Myocardial Infarction. Mulder DJ, van Haelst PL, Graaff R. Circulation. 2005;II(112):371.

224. Skin autofluorescence is elevated in patients with stable coronary artery disease and is associated with serum levels of neopterin and the soluble receptor for advanced glycation end products. Mulder DJ, van Haelst PL, Gross S, et al. Atherosclerosis. 2008;197(1):217-223. doi:10.1016/j.atherosclerosis.2007.03.027

225. The effect of aggressive versus conventional lipid-lowering therapy on markers of inflammatory and oxidative stress. Mulder DJ, van Haelst PL, Wobbes MH, et al. Cardiovasc Drugs Ther. 2007;21(2):91-97. doi:10.1007/s10557-007-6010-x

226. AGE and their receptor RAGE in systemic autoimmune diseases: an inflammation propagating factor contributing to accelerated atherosclerosis. Nienhuis HLA, Westra J, Smit AJ, Limburg PC, Kallenberg CGM, Bijl M. Autoimmunity. 2009;42(4):302-304. doi:10.1080/08916930902831746

227. Skin autofluorescence is increased in patients with carotid artery stenosis and peripheral artery disease. Noordzij MJ, Lefrandt JD, Loeffen EAH, et al. Int J Cardiovasc Imaging. 2012;28(2):431-438. doi:10.1007/s10554-011-9805-6

228. Advanced glycation end products in patients with cerebral infarction. Ohnuki Y, Nagano R, Takizawa S, Takagi S, Miyata T. Intern Med. 2009;48(8):587-591. doi:10.2169/internalmedicine.48.1390

229. Skin autofluorescence, a measure of tissue accumulation of advanced glycation end products, is associated with subclinical atherosclerosis in coronary and carotid arteries. Pan J. Published online 2022.

230. Skin autofluorescence, 5-year mortality, and cardiovascular events in peripheral arterial disease: all that glitters is surely not gold. Schmidt AM. Arterioscler Thromb Vasc Biol. 2014;34(4):697-699. doi:10.1161/ATVBAHA.114.303419

231. Association of Skin Autofluorescence Levels With Kidney Function Decline in Patients With Peripheral Artery Disease. Schutte E, de Vos LC, Lutgers HL, et al. Arterioscler Thromb Vasc Biol. 2016;36(8):1709-1714. doi:10.1161/ATVBAHA.116.307771

232. Advanced glycation endproducts in chronic heart failure. Smit AJ, Hartog JWL, Voors AA, van Veldhuisen DJ. Ann N Y Acad Sci. 2008;1126:225-230. doi:10.1196/annals.1433.038

233. Skin autofluorescence as proxy of tissue AGE accumulation is dissociated from SCORE cardiovascular risk score, and remains so after 3 years. Tiessen AH, Jager W, ter Bogt NCW, et al. Clin Chem Lab Med. 2014;52(1):121-127. doi:10.1515/cclm-2012-0825

234. Relationship between tissue glycation measured by autofluorescence and pulse wave velocity in young and elderly non-diabetic populations. Watfa G, Soulis G, Tartagni E, et al. Diabetes Metab. 2012;38(5):413-419. doi:10.1016/j.diabet.2012.04.004

235. Role of Advanced Glycation Endproduct (AGE)-Receptor for Advanced Glycation Endproduct (RAGE) Axis in Cardiovascular Disease and Its Therapeutic Intervention. Yamagishi SI. Circ J. 2019;83(9):1822-1828. doi:10.1253/circj.CJ-19-0618

236. Evaluation of tissue accumulation levels of advanced glycation end products by skin autofluorescence: A novel marker of vascular complications in high-risk patients for cardiovascular disease. Yamagishi SI, Fukami K, Matsui T. Int J Cardiol. 2015;185:263-268. doi:10.1016/j.ijcard.2015.03.167

237. Advanced glycation end products and bone – How do we measure them and how do they correlate with bone mineral density and fractures? A systematic review and evaluation of precision of measures. Brandt IAG, Jessen MH, Rimestad DE, Højgaard MKF, Vestergaard P. Bone. Published online September 26, 2022:116569. doi:10.1016/j.bone.2022.116569

238. It’s all in our skin-Skin autofluorescence-A promising outcome predictor in cardiac surgery: A single centre cohort study. Hofmann B, Gerull KA, Bloch K, et al. PLoS One. 2020;15(6):e0234847. doi:10.1371/journal.pone.0234847

239. Skin autofluorescence as a novel predictor of acute kidney injury after liver resection. Krasnodebski M, Grat K, Morawski M, et al. World J Surg Oncol. 2021;19(1):276. doi:10.1186/s12957-021-02394-0

240. Skin Autofluorescence Measurement as Initial Assessment of Hepatic Parenchyma Quality in Patients Undergoing Liver Resection. Krasnodebski M, Morawski M, Borkowski J, et al. SJ Clin Med. 2022;11(18):5341. doi:10.3390/jcm11185341

241. Post-translational modification-derived products are associated with frailty status in elderly subjects. Mahmoudi R, Jaisson S, Badr S, et al. Clin Chem Lab Med. 2019;57(8):1153-1161. doi:10.1515/cclm-2018-1322

242. Accumulation of advanced glycation end products evaluated by skin autofluorescence and incident frailty in older adults from the Bordeaux Three-City cohort. Pilleron S, Rajaobelina K, Tabue Teguo M, et al. PLoS One. 2017;12(10):e0186087. doi:10.1371/journal.pone.0186087

243. Increased skin autofluorescence after colorectal operation reflects surgical stress and postoperative outcome. Pol HWD, Sibma E, Zeebregts CJ, Pierik EGJM, Meerwaldt R. Am J Surg. 2011;202(5):583-589. doi:10.1016/j.amjsurg.2010.10.019

244. Advanced Glycation End Product (AGE) and Soluble Receptor of AGE (sRAGE) Levels in Relation to Periodontitis Severity and as Putative 3-Year Outcome Predictors in Patients Undergoing Coronary Artery Bypass Grafting (CABG). Reichert S, Hofmann B, Kohnert M, et al.J Clin Med. 2022;11(14):4105. doi:10.3390/jcm11144105

245. Advanced glycation end products for preoperative frailty screening in older cardiac surgery patients. Smoor RM, van Dongen EPA, Verwijmeren L, et al. J Am Geriatr Soc. Published online April 6, 2023. doi:10.1111/jgs.18361

246. Skin autofluorescence, a non-invasive biomarker of advanced glycation end-products (AGEs), is associated with frailty: The Rotterdam study. Waqas K, Chen J, Rivadeneira F, Uitterlinden AG, Voortman T, Zillikens MC. J Gerontol A Biol Sci Med Sci. Published online January 31, 2022:glac025. doi:10.1093/gerona/glac025

AGE Reader in altre condizioni patologiche

247. Morbid obesity leads to increased skin autofluorescence independent of metabolic syndrome components. Apaydin T, Yavuz DG. Turk J Med Sci. 2022;52(4):1085-1092. doi:10.55730/1300-0144.5411

248. Skin autofluorescence as a tool for cardiovascular risk estimation in patients with rheumatoid arthritis. Bakker-Aling SH, van Woerkom JM, Zomer TP, Buscher HCJL, van Bemmel T. Eur J Intern Med. 2019;66:e7-e8. doi:10.1016/j.ejim.2019.06.011

249. Skin autofluorescence, a marker of advanced glycation end products and oxidative stress, is increased in recently preeclamptic women. Blaauw J, Smit AJ, van Pampus MG, et al. Am J Obstet Gynecol. 2006;195(3):717-722. doi:10.1016/j.ajog.2006.06.086

250. Skin autofluorescence as marker of tissue advanced glycation end-products accumulation in formerly preeclamptic women. Coffeng SM, Blaauw J, Souwer ETD, et al. Hypertens Pregnancy. 2011;30(2):231-242. doi:10.3109/10641955.2010.484085

251. Increased dietary intake of ultraprocessed foods and mitochondrial metabolism alterations in pediatric obesity. Coppola S, Paparo L, Trinchese G, et al. Sci Rep. 2023;13:12609. doi:10.1038/s41598-023-39566-9

252. The Effects of Dietary Advanced Glycation End-Products on Neurocognitive and Mental Disorders. D’Cunha NM, Sergi D, Lane MM, et al. Nutrients. 2022;14(12):2421. doi:10.3390/nu14122421

253. Advanced glycation endproducts are increased in rheumatoid arthritis patients with controlled disease. De Groot L, Hinkema H, Westra J, et al. Arthritis Res Ther. 2011;13(6):R205.
doi:10.1186/ar3538

254. Does reduction of disease activity improve early markers of cardiovascular disease in newly diagnosed rheumatoid arthritis patients? De Groot L, Jager NA, Westra J, et al. Rheumatology (Oxford). 2015;54(7):1257-1261. doi:10.1093/rheumatology/keu459

255. Accumulation of advanced glycation endproducts in patients with systemic lupus erythematosus. De Leeuw K, Graaff R, de Vries R, et al. Rheumatology (Oxford). 2007;46(10):1551-1556. doi:10.1093/rheumatology/kem215

256. Increased accumulation of advanced glycation endproducts in patients with Wegener’s granulomatosis. De Leeuw K, Nienhuis H, Smit A, Stegeman C, Kallenberg C, Bijl M. Ann Rheum Dis. 2010;69(3):625-627. doi:10.1136/ard.2009.123851

257. Advanced glycation end products and the absence of premature atherosclerosis in glycogen storage disease Ia. Den Hollander NC, Mulder DJ, Graaff R, et al. J Inherit Metab Dis. 2007;30(6):916-923. doi:10.1007/s10545-007-0507-0

258. Noninvasive Skin Autofluorescence of Advanced Glycation End Products for Detecting Ossification of the Posterior Longitudinal Ligament in the Thoracic Spine. Doi T, Horii C, Tozawa K, et al. Spine (Phila Pa 1976). 2023;48(4):E40-E45. doi:10.1097/BRS.0000000000004516

259. Surface Area of Detachment, Proliferative Vitreoretinopathy, and Pulse Pressure, but not AGEs, are Associated With Retinal Redetachment. Fokkens BT, Mulder DJ, Nugteren MB, et al. Invest Ophthalmol Vis Sci. 2016;57(15):6633-6638. doi:10.1167/iovs.16-20735

260. Association between Advanced Glycation End-Products, Carotenoids, and Severe Erectile Dysfunction. Fujita N, Ishida M, Iwane T, et al. World J Mens Health. Published online January 3, 2023. doi:10.5534/wjmh.220154

261. Plasma advanced glycation end-products and skin autofluorescence are increased in COPD. Gopal P, Reynaert NL, Scheijen JLJM, et al. Eur Respir J. 2014;43(2):430-438. doi:10.1183/09031936.00135312

262. Accumulation of advanced glycation end (AGEs) products in intensive care patients: an observational, prospective study. Greven WL, Smit JM, Rommes JH, Spronk PE. BMC Clin Pathol. 2010;10:4. doi:10.1186/1472-6890-10-4

263. Accumulation rate of advanced glycation end products in recent onset psychosis: A longitudinal study. Hagen JM, Sutterland AL, Edrisy S, Tan HL, de Haan L. Psychiatry Res. 2020;291:113192. doi:10.1016/j.psychres.2020.113192

264. Advanced Glycation End Products in Recent-Onset Psychosis Indicate Early Onset of Cardiovascular Risk. Hagen JM, Sutterland AL, Koeter MW, Lutter R, Cohen D, de Haan L. J Clin Psychiatry. 2017;78(9):1395-1401. doi:10.4088/JCP.16m10972

265. Skin autofluorescence of advanced glycation end products and mortality in affective disorders in the lifelines cohort study: A mediation analysis. Hagen JM, Sutterland AL, Liefers T, et al. J Affect Disord. 2021;282:1082-1089. doi:10.1016/j.jad.2020.12.202

266. Advanced glycation end products as a biomarker for incisional hernia. Harlaar JJ, Eker HH, Vakalopoulos KA, et al. Hernia. 2017;21(4):537-541. doi:10.1007/s10029-017-1610-2

267. Skin autofluorescence, as marker of accumulation of advanced glycation endproducts and of cumulative metabolic stress, is not increased in patients with systemic sclerosis. Hettema ME, Bootsma H, Graaff R, de Vries R, Kallenberg CGM, Smit AJ. Int J Rheumatol. 2011;2011:417813. doi:10.1155/2011/417813

268. Local differences in skin autofluorescence may not reflect similar differences in oxidative stress exposure. Hettema M, Smit AJ. J Rheumatol. 2013;40(2):206. doi:10.3899/jrheum.121060

269. The association between skin autofluorescence and mean deviation in patients with open-angle glaucoma. Himori N, Kunikata H, Kawasaki R, et al. Br J Ophthalmol. 2017;101(2):233-238. doi:10.1136/bjophthalmol-2016-309504

270. The association between systemic oxidative stress and ocular blood flow in patients with normal-tension glaucoma. Himori N, Kunikata H, Shiga Y, et al. Graefes Arch Clin Exp Ophthalmol. 2016;254(2):333-341. doi:10.1007/s00417-015-3203-z

271. Advanced glycation end products in the skin are enhanced in COPD. Hoonhorst SJM, Lo Tam Loi AT, Hartman JE, et al. Metabolism. 2014;63(9):1149-1156. doi:10.1016/j.metabol.2014.06.006

272. Advanced glycation endproducts and their receptor in different body compartments in COPD. Hoonhorst SJM, Lo Tam Loi AT, Pouwels SD, et al. Respir Res. 2016;17:46. doi:10.1186/s12931-016-0363-2

273. Skin Autofluorescence Examination as a Diagnostic Tool for Mild Cognitive Impairment in Healthy People. Igase M, Ohara M, Igase K, et al. J Alzheimers Dis. 2017;55(4):1481-1487. doi:10.3233/JAD-160917

274. Traditional and emerging indicators of cardiovascular risk in chronic obstructive pulmonary disease. John M, McKeever TM, Haddad MA, et al. Chron Respir Dis. 2016;13(3):247-255. doi:10.1177/1479972316636995

275. Relationship between advanced glycation end-product accumulation and low skeletal muscle mass in Japanese men and women. Kato M, Kubo A, Sugioka Y, et al. Geriatr Gerontol Int. 2017;17(5):785-790. doi:10.1111/ggi.12787

276. Increased advanced glycation end-products (AGEs) assessed by skin autofluorescence in schizophrenia. Kouidrat Y, Amad A, Desailloud R, et al. J Psychiatr Res. 2013;47(8):1044-1048. doi:10.1016/j.jpsychires.2013.03.016

277. Skin autofluorescence in children with and without obesity. Lentferink YE, van Teeseling L, Knibbe CAJ, van der Vorst MMJ. J Pediatr Endocrinol Metab. 2019;32(1):41-47. doi:10.1515/jpem-2018-0237

278. Reduction of cutaneous advanced glycation end products levels after effective psoriasis treatment. Maurelli M, Bellinato F, Gisondi P, Girolomoni G.J Eur Acad Dermatol Venereol. 2022;36(8):e629-e631. doi:10.1111/jdv.18090

279. Advanced Glycation End Products and Psoriasis. Maurelli M, Gisondi P, Girolomoni G. Vaccines (Basel). 2023;11(3):617. doi:10.3390/vaccines11030617

280. Skin autofluorescence is high in patients with cirrhosis – further arguing for the implication of Advanced Glycation End products. Maury E, Vergniol J, Ledinghen V de, Rigalleau V. J Hepatol. 2011;54(5):1079-1080. doi:10.1016/j.jhep.2010.10.012

281. The Course of Skin and Serum Biomarkers of Advanced Glycation Endproducts and Its Association with Oxidative Stress, Inflammation, Disease Severity, and Mortality during ICU Admission in Critically Ill Patients: Results from a Prospective Pilot Study. Meertens JH, Nienhuis HL, Lefrandt JD, et al. PLoS One. 2016;11(8):e0160893. doi:10.1371/journal.pone.0160893

282. Skin advanced glycation end-product accumulation is negatively associated with calcaneal osteo-sono assessment index among non-diabetic adult Japanese men. Momma H, Niu K, Kobayashi Y, et al. Osteoporos Int. 2012;23(6):1673-1681. doi:10.1007/s00198-011-1753-4

283. Skin advanced glycation end product accumulation and muscle strength among adult men. Momma H, Niu K, Kobayashi Y, et al. Eur J Appl Physiol. 2011;111(7):1545-1552. doi:10.1007/s00421-010-1779-x

284. Skin autofluorescence is increased in systemic lupus erythematosus but is not reflected by elevated plasma levels of advanced glycation endproducts. Nienhuis HL, de Leeuw K, Bijzet J, et al. Rheumatology (Oxford). 2008;47(10):1554-1558. doi:10.1093/rheumatology/ken302

285. Association Between Accumulation of Advanced Glycation End-Products and Hearing Impairment in Community-Dwelling Older People: A Cross-Sectional Sukagawa Study. Niihata K, Takahashi S, Kurita N, et al. J Am Med Dir Assoc. 2018;19(3):235-239.e1. doi:10.1016/j.jamda.2017.09.008

286. Advanced Glycation End Products are Increased in the Skin and Blood of Patients with Severe Psoriasis. Papagrigoraki. doi:10.2340/00015555-2661

287. Vascular aspects of Fabry disease in relation to clinical manifestations and elevations in plasma globotriaosylsphingosine. Rombach SM, van den Bogaard B, de Groot E, et al. Hypertension. 2012;60(4):998-1005. doi:10.1161/HYPERTENSIONAHA.112.195685

288. Advanced glycation end-products in morbid obesity and after bariatric surgery: When glycemic memory starts to fail. Sánchez E, Baena-Fustegueras JA, de la Fuente MC, et al. Endocrinol Diabetes Nutr. 2017;64(1):4-10. doi:10.1016/j.endinu.2016.09.009

289. There a Link between Obesity Indices and Skin Autofluorescence? A Response from the ILERVAS Project. Sánchez E, Sánchez M, López-Cano C, et al. Is Nutrients. 2022;15(1):203. doi:10.3390/nu15010203

290. Autofluorescence of Skin Advanced Glycation End Products as a Risk Factor for Open Angle Glaucoma: The ALIENOR Study. Schweitzer C, Cougnard-Gregoire A, Rigalleau V, et al. Invest Ophthalmol Vis Sci. 2018;59(1):75-84. doi:10.1167/iovs.17-22316

291. Associations of advanced glycation end-products with cognitive functions in individuals with and without type 2 diabetes: the maastricht study. Spauwen PJJ, van Eupen MGA, Köhler S, et al. J Clin Endocrinol Metab. 2015;100(3):951-960. doi:10.1210/jc.2014-2754

292. Skin advanced glycation end products in HIV infection are increased and predictive of development of cardiovascular events. Sprenger HG, Bierman WF, Martes MI, Graaff R, van der Werf TS, Smit AJ. AIDS. 2017;31(2):241-246. doi:10.1097/QAD.0000000000001297

293. Cognitive Impairment in Long-Term Survivors of Testicular Cancer More Than 20 Years after Treatment. Stelwagen J, Meuleman AT, Lubberts S, et al. Cancers (Basel). 2021;13(22):5675. doi:10.3390/cancers13225675

294. Association of skin autofluorescence and carotid intima-media thickness in acromegaly patients. Uygur MM, Yasar M, Uygur SÖ, Yazici DD, Yavuz DG. Minerva Endocrinol (Torino). Published online June 16, 2023. doi:10.23736/S2724-6507.23.03951-9

295. Skin autofluorescence, a non-invasive biomarker for advanced glycation end products, is associated with the metabolic syndrome and its individual components. Van Waateringe RP, Slagter SN, van Beek AP, et al. Diabetol Metab Syndr. 2017;9:42. doi:10.1186/s13098-017-0241-1

296. Skin autofluorescence, a non-invasive biomarker of advanced glycation end products, and its relation to radiographic and MRI based osteoarthritis. Waqas K, Szilagyi IA, Schiphof D, et al. Osteoarthritis Cartilage. Published online September 7, 2022:S1063-4584(22)00832-9. doi:10.1016/j.joca.2022.08.014

297. Skin Autofluorescence, a Noninvasive Biomarker for Advanced Glycation End-products, Is Associated With Sarcopenia. Waqas K, Zillikens MC. The Journal of Clinical Endocrinology & Metabolism. Published online August 28, 2021. doi:https://doi.org/10.1210/clinem/dgab632

298. Use of skin advanced glycation end product levels measured using a simple noninvasive method as a biological marker for the diagnosis of neuropsychiatric diseases. Yamashita H, Fukushima E, Shimomura K, et al. Int J Methods Psychiatr Res. 2020;29(2):e1824. doi:10.1002/mpr.1824

299. Measures of lung function and their relationship with advanced glycation end-products. Zaigham S, Persson M, Jujic A, et al. ERJ Open Res. 2020;6(2):00356-02019. doi:10.1183/23120541.00356-2019

300. Comparison of advanced glycation end products concentration in the skin among patients with rheumatic diseases, with and without comorbid depression: a case–control study. Zuchowski P, Dura M, Kazmierczak K, Meder G, Waszczak-Jeka M, Jeka D. Rheumatol Int. 2023;43(10):1829-1834. doi:10.1007/s00296-023-05393-4

301. A Prospective Analysis of Skin and Fingertip Advanced Glycation End-Product Devices in Healthy Volunteers. Adl Amini D, Moser M, Chiapparelli E, et al. J Clin Med. 2022;11(16):4709. doi:10.3390/jcm11164709

302. N-epsilon-(carboxyethyl)lysine, a product of the chemical modification of proteins by methylglyoxal, increases with age in human lens proteins. Ahmed MU, Brinkmann Frye E, Degenhardt TP, Thorpe SR, Baynes JW. Biochem J. 1997;324 ( Pt 2):565-570. doi:10.1042/bj3240565

303. The AGE Reader: A non-invasive method to assess long-term tissue damage. Atzeni IM, van de Zande SC, Westra J, Zwerver J, Smit AJ, Mulder DJ. Methods. Published online February 23, 2021:S1046-2023(21)00059-1. doi:10.1016/j.ymeth.2021.02.016

304. Is skin autofluorescence (SAF) representative of dermal advanced glycation endproducts (AGEs) in dark skin? A pilot study. Atzeni IM, Boersema J, Pas HH, et al. Heliyon. 2020;6(11):e05364. doi:10.1016/j.heliyon.2020.e05364

305. Skin autofluorescence, a non-invasive marker of advanced glycation end products: clinical relevance and limitations. Da Moura Semedo C, Webb M, Waller H, Khunti K, Davies M. Postgrad Med J. 2017;93(1099):289-294. doi:10.1136/postgradmedj-2016-134579

306. Accumulation of Maillard reaction products in skin collagen in diabetes and aging. Dyer DG, Dunn JA, Thorpe SR, et al. J Clin Invest. 1993;91(6):2463-2469. doi:10.1172/JCI116481

307. GWAS identifies an NAT2 acetylator status tag single nucleotide polymorphism to be a major locus for skin fluorescence. Eny KM, Lutgers HL, Maynard J, et al. Diabetologia. 2014;57(8):1623-1634. doi:10.1007/s00125-014-3286-9

308. Instrumentation for the measurement of autofluorescence in human skin. Graaff R, Meerwaldt R, Lutgers HL, et al. 2005;5692:111-118. doi:10.1117/12.588984

309. Advanced glycation end product associated skin autofluorescence: a mirror of vascular function? Hofmann B, Adam AC, Jacobs K, et al. Exp Gerontol. 2013;48(1):38-44. doi:10.1016/j.exger.2012.04.011

310. Association of advanced glycation end products, evaluated by skin autofluorescence, with lifestyle habits in a general Japanese population. Isami F, West BJ, Nakajima S, Yamagishi SI. J Int Med Res. 2018;46(3):1043-1051. doi:10.1177/0300060517736914

311. Reference values of skin autofluorescence. Koetsier M, Lutgers HL, de Jonge C, Links TP, Smit AJ, Graaff R. Diabetes Technol Ther. 2010;12(5):399-403. doi:10.1089/dia.2009.0113

312. Skin autofluorescence for the risk assessment of chronic complications in diabetes: a broad excitation range is sufficient. Koetsier M, Lutgers H, Smit AJ, et al. Opt Express. 2009;17(2):509-519. doi:10.1364/oe.17.000509

313. Skin color independent assessment of aging using skin autofluorescence. Koetsier M, Nur E, Chunmao H, et al. Opt Express. 2010;18(14):14416-14429. doi:10.1364/OE.18.014416

314. Verification of skin autofluorescence values by mass spectrometry in adolescents with type 1 diabetes: brief report. Mácsai E, Takáts Z, Derzbach L, Körner A, Vásárhelyi B. Diabetes Technol Ther. 2013;15(3):269-272. doi:10.1089/dia.2012.0251

315. Simple non-invasive assessment of advanced glycation endproduct accumulation. Meerwaldt R, Graaff R, Oomen PHN, et al. Diabetologia. 2004;47(7):1324-1330. doi:10.1007/s00125-004-1451-2

316. Simple noninvasive measurement of skin autofluorescence. Meerwaldt R, Links T, Graaff R, et al. Ann N Y Acad Sci. 2005;1043:290-298. doi:10.1196/annals.1333.036

317. Evaluation of the glycative stress by non-invansive skin AGEs measurement devices. Morita Y. Accessed October 5, 2021. https://www.jstage.jst.go.jp/article/gsr/6/2/6_92/_article/-char/en

319. Skin autofluorescence, a novel marker for glycemic and oxidative stress-derived advanced glycation endproducts: an overview of current clinical studies, evidence, and limitations. Mulder DJ, Water TVD, Lutgers HL, et al. Diabetes Technol Ther. 2006;8(5):523-535. doi:10.1089/dia.2006.8.523

320. Dermal factors influencing measurement of skin autofluorescence. Noordzij MJ, Lefrandt JD, Graaff R, Smit AJ. Diabetes Technol Ther. 2011;13(2):165-170. doi:10.1089/dia.2010.0123

321. Reference values of skin autofluorescence as an estimation of tissue accumulation of advanced glycation end products in a general Slovak population. Simon Klenovics K, Kollárová R, Hodosy J, Celec P, Sebeková K. Diabet Med. 2014;31(5):581-585. doi:10.1111/dme.12326

322. Prevalence, incidence and mortality of type 2 diabetes mellitus revisited: a prospective population-based study in The Netherlands (ZODIAC-1). Ubink-Veltmaat LJ, Bilo HJG, Groenier KH, Houweling ST, Rischen RO, Meyboom-de Jong B. Eur J Epidemiol. 2003;18(8):793-800. doi:10.1023/a:1025369623365

323. Reference values for the Chinese population of skin autofluorescence as a marker of advanced glycation end products accumulated in tissue. Yue X, Hu H, Koetsier M, Graaff R, Han C. Diabet Med. 2011;28(7):818-823. doi:10.1111/j.1464-5491.2010.03217.x